NK
NKGen Biotech, Inc. Common Stock
NKGN · OTC
$0.01 +0.00% (+$0.00)
1M +471.43%
Market Cap $1.57M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
91 /100
Cheap EV/EBITDA 1.85x
P/S 2.40x
P/E N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 50.00%
Net margin 3,612.58%
Op. margin 3,682.67%
Quality
58 /100
Average ROIC 2,118.41%
ROA 148.68%
Asset turnover 0.04x
Debt
45 /100
Moderate Current ratio 0.05x
Int. coverage 3.08x
Net debt/EBITDA 1.77x
Stability
37 /100
Moderate Beta 0.72x
EPS volatility 211.35%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre NKGN
Online
Despre companie
NKGen Biotech, Inc. Common Stock (NKGEN) is a biotechnology company specializing in the development and research of therapeutic products utilizing natural killer (NK) cells. Their main focus is on harnessing the body's immune system to fight against cancer and other diseases.
Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Y. Song
Employees
26
Headquarters
Santa Ana